SWAV
FY2026 EPS Estimate
$7.20
FY2026E EPS$7.20
FY2027E EPS$8.47

Analyst Sentiment

Wall St. Consensus
Hold
12 analysts·Moderate coverage
56
Score
4 Buy (33%)7 Hold (58%)1 Sell (9%)
Rating Breakdown
Strong Buy
00%
Buy
433%
Hold
758%
Sell
18%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$175.00
-47.7%
Consensus
$239.50
-28.5%
Bull
$360.00
+7.5%
12-Month Target Range12 analysts
$175.00$239.50$360.00
Current $334.75Consensus
Current Price
$334.75
Above Consensus
$95.25

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+12.54%
EPS+17.50%
FY2028
Rev+12.97%
EPS+18.36%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028E
Revenue Avg$1.34B$1.50B$1.70B
Low$1.32B$1.50B$1.70B
High$1.35B$1.50B$1.70B
EBITDA Avg$432M$478M$567M
Low$359M$478M$567M
High$457M$478M$567M
EBIT Avg$381M$412M$488M
Low$308M$412M$488M
High$406M$412M$488M
Net Income Avg$299M$323M$383M
Low$241M$323M$383M
High$318M$323M$383M
EPS Avg$7.20$8.47$10.02
Low$6.31$8.47$10.02
High$8.33$8.47$10.02
Analysts (Rev / EPS)9 / 88 / 53 / 6
Quarterly
MetricQ3 2026Q4 2026
Revenue Avg$338M$371M
Low$338M$371M
High$338M$371M
EBITDA Avg$104M$115M
Low$104M$115M
High$104M$115M
EBIT Avg$93M$104M
Low$93M$104M
High$93M$104M
Net Income Avg$72M$80M
Low$72M$80M
High$72M$80M
EPS Avg$1.86$2.07
Low$1.86$2.07
High$1.86$2.07
Analysts (Rev / EPS)2 / 12 / 1

Earnings Surprises

Recent Analyst Actions

Apr 5, 2024Johnson Rice
ShockWave Medical downgraded to Hold from Buy at Canaccord
Target:$335.00
+2.9%from $325.48
Apr 2, 2024Piper Sandler
Shockwave Medical (SWAV) PT Raised to $360 at Piper Sandler
Target:$360.00
+12.3%from $320.51
Jan 6, 2023Morgan Stanley
Morgan Stanley Maintains Equal-Weight on ShockWave Medical, Lowers Price Target to $224
Target:$224.00
+7.6%from $208.17
Aug 29, 2022Piper Sandler
Piper Sandler Maintains Overweight on ShockWave Medical, Raises Price Target to $338
Target:$338.00
+11.0%from $304.44
Aug 9, 2022Morgan Stanley
Morgan Stanley Maintains Equal-Weight on ShockWave Medical, Raises Price Target to $255
Target:$255.00
-1.5%from $258.93
Aug 9, 2022Wells Fargo
Wells Fargo Maintains Overweight on ShockWave Medical, Raises Price Target to $255
Target:$255.00
+15.0%from $221.77
Aug 9, 2022Piper Sandler
Piper Sandler Maintains Overweight on ShockWave Medical, Raises Price Target to $278
Target:$278.00
+25.4%from $221.77
Jul 15, 2022Morgan Stanley
Morgan Stanley Maintains Equal-Weight on ShockWave Medical, Raises Price Target to $201
Target:$201.00
-4.2%from $209.90
May 10, 2022Morgan Stanley
Morgan Stanley Maintains Equal-Weight on ShockWave Medical, Lowers Price Target to $180
Target:$180.00
+34.9%from $133.39
May 10, 2022Wells Fargo
Wells Fargo Maintains Overweight on ShockWave Medical, Lowers Price Target to $176
Target:$176.00
+51.8%from $115.91
May 10, 2022Leerink Partners
SVB Leerink Maintains Outperform on ShockWave Medical, Lowers Price Target to $175
Target:$175.00
+51.0%from $115.91
May 10, 2022Piper Sandler
ShockWave pullback an opportunity after 'strong' Q1, says Piper Sandler
Target:$245.00
+111.4%from $115.91
Mar 3, 2022Bank of America Securities
Shockwave Medical (SWAV) Stock: $200 Price Target And Buy Rating
Target:$200.00
+12.2%from $178.22
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.